Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines
JAMA · 05.05.2026 · 335 (17) · 1475
DOI: 10.1001/jama.2026.3526 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 05.05.2026. Verfasst von S Sean Tu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses use of skinny labeling to reduce the price of brand-name drugs, impediments to timely generic market entry and affordability, and inducement liability that causes marketing uncertainty.
Autor:innen und Institutionen
- Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- University of Alabama School of Law, Tuscaloosa.
- Department of Medicine, University of Chicago, Chicago, Illinois.
Zitieren
APA
Tu, S. S., Tessema, F. A., & Kesselheim, A. S. (2026). Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines. JAMA, 335(17), 1475. https://doi.org/10.1001/jama.2026.3526
Vancouver
Tu SS, Tessema FA, Kesselheim AS. Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines. JAMA. 2026;335(17):1475. doi:10.1001/jama.2026.3526
BibTeX
@article{Tu2026,
author = {Tu, S Sean and Tessema, Frazer A and Kesselheim, Aaron S},
title = {Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines},
journal = {JAMA},
year = {2026},
volume = {335},
number = {17},
pages = {1475},
doi = {10.1001/jama.2026.3526}
}
EUVIMED